4,648
Participants
Start Date
September 15, 2007
Primary Completion Date
May 28, 2008
Study Completion Date
May 28, 2008
FluBlok®
Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
Placebo
Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular
Regional Clinical Research, Inc., Endwell
Rochester Medical Center, Rochester
Primary Physicians Research - Pediatric Alliance St. Clair, Pittsburgh
Primary Physicians Research, Pittsburgh
University of Maryland - Baltimore, Baltimore
University of Virginia Health System, Charlottesville
Carolina Medical Trials, Winston-Salem
University Clinical Research, Inc, Pembroke Pines
Vanderbilt University Medical Center, Nashville
Kentucky pediatric /Adult Research, Bardstown
Sterling Research, Cincinnati
Marshfield Clinic, Marshfield
Saint Louis University, St Louis
Vince and Associates, Overland Park
Meridian Clinical Research, Omaha
Benchmarch Research - New Orleans, Metairie
Benchmark Research - Fort Worth, Fort Worth
Benchmark Research - San Angelo, San Angelo
Baylor College of Medicine, Houston
Benchmarch Research - Austin, Austin
Jean Brown Research, Salt Lake City
Impact Clinical Trials, Beverly Hills
Benchmark Research - San Francisco, San Francisco
Benchmark Research - Sacramento, Sacramento
Lead Sponsor
Protein Sciences Corporation
INDUSTRY
Sanofi
INDUSTRY